Exane Derivatives’s Target TGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-81
Closed -$17.2K 926
2022
Q1
$17.2K Buy
+81
New +$17.5K ﹤0.01% 668
2021
Q4
Sell
-1,737
Closed -$397K 975
2021
Q3
$397K Buy
1,737
+26
+2% +$6.51K 0.1% 227
2021
Q2
$431K Buy
1,711
+1,635
+2,151% +$358K 0.1% 216
2021
Q1
$15.1K Sell
76
-161
-68% -$30.1K ﹤0.01% 583
2020
Q4
$41.8K Sell
237
-3,583
-94% -$598K 0.01% 471
2020
Q3
$601K Buy
3,820
+3,313
+653% +$455K 0.17% 116
2020
Q2
$60.8K Sell
507
-431
-46% -$49.2K 0.02% 341
2020
Q1
$87.2K Sell
938
-580
-38% -$64.4K 0.02% 296
2019
Q4
$178K Sell
1,518
-282
-16% -$33.1K 0.03% 268
2019
Q3
$192K Sell
1,800
-47,574
-96% -$4.53M 0.03% 260
2019
Q2
$4.28M Sell
49,374
-1,104
-2% -$89.2K 0.75% 27
2019
Q1
$4.05M Sell
50,478
-2,685
-5% -$196K 0.8% 31
2018
Q4
$3.51M Buy
53,163
+17,109
+47% +$1.32M 0.63% 37
2018
Q3
$3.18M Buy
36,054
+34,814
+2,808% +$2.9M 0.6% 43
2018
Q2
$95.1K Sell
1,240
-30,471
-96% -$2.24M 0.02% 340
2018
Q1
$2.19M Buy
31,711
+18,046
+132% +$1.31M 0.44% 52
2017
Q4
$891K Buy
13,665
+9,962
+269% +$601K 0.15% 107
2017
Q3
$218K Sell
3,703
-1,956
-35% -$110K 0.04% 195
2017
Q2
$296K Buy
5,659
+292
+5% +$16K 0.06% 175
2017
Q1
$296K Buy
+5,367
New +$334K 0.07% 164
2016
Q4
Sell
-6,514
Closed -$447K 679
2016
Q3
$447K Sell
6,514
-740
-10% -$53K 0.07% 160
2016
Q2
$506K Sell
7,254
-166,742
-96% -$12.4M 0.08% 130
2016
Q1
$14.3M Buy
+173,996
New +$13.1M 1.9% 17
2015
Q4
Sell
-243,418
Closed -$19.1M 560
2015
Q3
$19.1M Sell
243,418
-50,613
-17% -$4.04M 2.42% 4
2015
Q2
$24M Buy
294,031
+286,697
+3,909% +$23.2M 2.58% 4
2015
Q1
$602K Sell
7,334
-1,257
-15% -$97.1K 0.07% 127
2014
Q4
$652K Buy
+8,591
New +$580K 0.09% 124

Other funds holding TGT

Exane Derivatives's TGT Position: Q2 2022 in Review

Exane Derivatives sold out of Target (TGT) in Q2 2022, closing a stake of 81 shares — an estimated $17.2K sold.

Exane Derivatives first reported a position in TGT in Q4 2014 and held it in 27 quarters. The position peaked at $24M in Q2 2015. 1,931 funds tracked by Wall St. Rank hold TGT as of Q2 2022.

  • Exane Derivatives reported no remaining Target position as of Q2 2022 after selling out during the quarter.
  • Exane Derivatives sold 81 Target shares in Q2 2022, an estimated $17.2K.
  • Exane Derivatives first reported a position in Target in Q4 2014 and held it in 27 quarters.
  • Exane Derivatives's Target position peaked at $24M in Q2 2015.
  • 1,931 funds tracked by Wall St. Rank held Target as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.